Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Data from the MPOWERED OLE and first presentation of open-label extension (OLE) data from 2nd year of OPTIMAL demonstrate the long-term safety and efficacy profile of Mycapssa®

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here